SCHEMBL4616004

SCHEMBL4616004

Cc1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)Cl

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
HSD11B1 P28845 1/20 0.44
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TSHR P16473 2/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 1/20 0.42
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
SFRP1 Q8N474 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8978705 0.88 HSD11B1 (0.47) LMNAHSD11B1ALDH1A1SMN1; SMN2TSHR
SCHEMBL4616083 0.85 LMNA (0.59) LMNAALDH1A1SMN1; SMN2TSHRHTT
SCHEMBL4618045 0.85 ALDH1A1 (0.60) LMNAHSD11B1ALDH1A1SMN1; SMN2TSHR
SCHEMBL4616375 0.83 LMNA (0.45) LMNAALDH1A1SMN1; SMN2TSHRHTT
SCHEMBL4616013 0.83 KMT2A (0.42) LMNAHSD11B1SMN1; SMN2TSHRHTT
SCHEMBL15867387 0.83 HSD11B1 (0.47) LMNAHSD11B1ALDH1A1SMN1; SMN2TSHR
SCHEMBL533075 0.82 KMT2A (0.51) LMNAALDH1A1SMN1; SMN2TSHRHTT
SCHEMBL31674581 0.82 KMT2A (0.51) LMNAALDH1A1SMN1; SMN2TSHRHTT
SCHEMBL4616900 0.82 HSD11B1 (0.47) LMNAHSD11B1ALDH1A1SMN1; SMN2TSHR
SCHEMBL4617002 0.81 SFRP1 (0.42) HSD11B1ALDH1A1HTR2CHTR2BSFRP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101208299-A Diarylsulfone sulfonamides and use therof WYETH CORP (US) 2008-06-25 CN disclosed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 LMNA 4608/4885HSD11B1 205/4885ALDH1A1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.